Immunocompetent C57BL/6 syngeneic mouse ovarian cancer models with defined genetic alterations

Hasmik Agadjanian1, Beth Y Karlan2,3, Christine S Walsh1,4

  • 1Women's Cancer Program, Cedars-Sinai Medical Center, Los Angeles, CA, USA.

Scientific Reports
|October 7, 2025
PubMed

Insights

Researchers developed new mouse models for ovarian cancer research. These syngeneic models mimic human disease, aiding the study of immunotherapies and improving early detection strategies.

Area of Science:

  • Oncology
  • Immunology
  • Genetics

Background:

  • Ovarian cancer is a leading cause of cancer death with limited early detection.
  • Syngeneic mouse models are crucial for studying ovarian cancer biology and immunotherapy preclinical research.
  • Diverse models are needed to reflect human ovarian cancer's heterogeneity.

Purpose of the Study:

  • To develop and characterize a panel of syngeneic ovarian cancer cell lines.
  • To incorporate specific genetic alterations found in human ovarian cancer.
  • To create models that closely mimic human serous ovarian cancer presentation.

Main Methods:

  • Generated syngeneic ovarian cancer cell lines with defined genetic alterations (TP53 deficiency, Hras mutation, Myc/Cyclin E overexpression).
  • Introduced oncogene drivers into TP53-/- cells for transformation.
  • Assessed cell transformation and tumor growth in nude and immunocompetent C57BL/6 mice.

Main Results:

  • Engineered cell lines exhibited transformation and growth upon oncogene driver introduction.
  • Intraperitoneal tumors showed high penetrance in mice.
  • Tumors displayed extensive metastasis and ascites, mirroring human ovarian cancer.

Conclusions:

  • The developed syngeneic ovarian cancer models accurately recapitulate human disease characteristics.
  • These models are valuable tools for preclinical immunotherapy research.
  • Further research with these models can advance ovarian cancer detection and treatment.